TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven mycosis fungoides or Sezary syndrome~  * Any stage~* Measurable disease with 1 or more indicator lesions~  * Evaluable disease for erythrodermic patients only~* At least 2 weeks since prior therapy, if documented progressive disease (PD)~* At least 4 weeks since prior therapy, if best response achieved without clear evidence of PD~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* At least 3 months~Hematopoietic:~* WBC at least 3,000/mm\^3~* Absolute granulocyte count at least 1,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.2 mg/dL~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No New York Heart Association class III or IV heart disease~* No cardiac pacemaker~* No clinically significant peripheral venous insufficiency~Other:~* No other malignancy within the past 5 years except:~  * Treated squamous cell or basal cell skin cancer~ * Treated carcinoma in situ of the cervix~ * Surgically treated other cancer~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active infection~* HIV negative~* No poorly controlled diabetes mellitus~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~Endocrine therapy:~* No concurrent steroids~Radiotherapy:~* See Disease Characteristics~* No concurrent radiotherapy~Surgery:~* Not specified~Other:~* No other concurrent proven or investigational antineoplastic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria (additional criteria apply):~1. Diagnosis of PHN made by primary treating physician and is experiencing pain for at least 3 months after the healing of a herpes zoster rash.~2. Subject is in general good health.~3. Females must be non-pregnant, non-lactating, and practicing an acceptable method of birth control or be surgically sterile or post-menopausal. Double barrier methods and abstinence are the only acceptable birth control methods for this study.~Exclusion Criteria (additional criteria apply):~1. Subject has a current acute disease or unstable chronic disease other than post herpetic neuralgia.~2. Subject has a clinically important history of a medical disorder (particularly cardiovascular, neurological \[e.g., diabetic neuropathy\], respiratory, or hepato-biliary systems \[e.g., Gilbert Syndrome\]) that would confound and/or interfere with the safety and efficacy evaluations defined in the protocol.~3. Subject is being treated for a medical condition that affects cardiac conduction.~4. Subject's plasma alanine aminotransferase (ALT) aspartate aminotransferase (AST), total bilirubin, and alkaline phosphatase (AP) values are not within the normal reference ranges.~5. Subject has a history of asthma requiring management for reactive airway disease in the last year.~6. Subject uses and is unwilling/unable to discontinue use of (A) Lyrica® (pregabalin), Cymbalta® (duloxetine), Neurontin® (gabapentin), topical lidocaine, topical capsaicin, or other medication specifically indicated (i.e., labeled) for the treatment of neuropathic pain, or (B) anticonvulsant medications to control post herpetic neuralgia.~7. Subject currently requires anticonvulsant medications to control seizures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T-62 100 mg bid (Type: EXPERIMENTAL): None
- T-62 200 mg bid (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Delayed Intubation of Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adult patients with confirmed COVID-19 and severe acute hypoxemic respiratory failure~Exclusion Criteria:~* Postoperative acute respiratory failure (within one week from surgery)~* After cardiac arrest~* Chronic hypoxemic respiratory failure~* Hypercapnic respiratory failure~* No full code~* Lack of equipoise of the clinical team~* Lack of informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early intubation (Type: ACTIVE_COMPARATOR): Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 \>92%) for at least 48 hours will undergo intubation.
- Delayed intubation (Type: ACTIVE_COMPARATOR): Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 \>92%) for at least 48 hours will continue to receive non-rebreather mask, high-flow nasal oxygen or non-invasive mechanical ventilation in an attempt to avoid intubation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient capable of giving informed consent~* Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods (Pathologically confirmed HCC by biopsy or HCC 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced MRI or CT or Lesion greater than 2 cm with probable imaging features of HCC and imaging findings of cirrhosis and/or portal hypertension or a serum alphafetoprotein (AFP) greater than 200 mg/mL.~* Patient not candidate for orthotopic liver transplantation at the Hospital of the University of Pennsylvania based on review of patient imaging and history at multidisciplinary Hepatic Tumor Conference at the Hospital of the University of Pennsylvania.~* Age 18 years old~* Albumin 2.4 g/dL; Total bilirubin 2 mg/dL; INR 1.5~* Creatinine 2.0 mg/dL, AST 121 IU/L; ALT 189 IU/L~* Child-Turcotte-Pugh Classification A or B~* Eastern Clinical Oncology Group performance status 0 or1.~Exclusion Criteria:~* Prior TACE~* Active GI hemorrhage within 2 weeks of study enrollment~* Ascites refractory to medical therapy~* Contraindication to receiving HCQ or TACE~* Unilobar HCC~* Contraindication to contrast enhanced MRI (i.e. unable to undergo follow-up imaging)~* Women who are pregnant~* Participation in another concurrent treatment protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TACE + HCQ (Type: EXPERIMENTAL): Subjects will receive HCQ plus standard of care TACE.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 5-20 weeks of gestation by ultrasound~* Miscarriage diagnosed by ultrasound~* Pregnancy tissue still present in utero, including an empty sac, and not completely expelled~Exclusion Criteria:~* Maternal age \< 18 years~* No visible pregnancy tissue on ultrasound~* Multiple fetal gestation (\> than singleton)~* Pregnancy was conceived using in vitro fertilization (IVF) with preimplantation genetic testing for aneuploidy (PGT-A) performed on the transferred embryo~* No microarray testing is planned on the product of conception~* Previous normal non-invasive prenatal testing (NIPT) or diagnostic testing (chorionic villous sampling or amniocentesis) in the current pregnancy~* Patient unable to provide consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Microdebrider-Assisted Inferior Turbinoplasty (MAIT) vs Submucous Resection (SMR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of chronic nasal obstruction with an exam finding of turbinate hypertrophy, with or without septal deviation will be eligible for the study.~* Failed medical treatment~* Have failed medical treatment for at least 1 month, and will be offered surgery~* Patients having Septoplasty at the same time as their turbinate reduction surgery.~Exclusion Criteria:~* Patients who have had previous turbinate reduction surgery will be excluded.~* Patients that have nasal polyps, chronic rhinosinusitis, adenoid hypertrophy, nasal tumors, or any other exam finding that would explain their symptoms of nasal obstruction other than enlarged inferior turbinates with or without septal deviation will be excluded.~* Patients who are diagnosed with purely bony inferior turbinate hypertrophy as discussed below.~* Patients on hormone or anticoagulation therapy and those who have a history of head and neck radiation therapy will be excluded.~* All study candidates will be assessed for external nasal valve collapse via the modified Cottle maneuver, and will be excluded if they exhibit significant external or internal nasal valve collapse as their primary cause of their nasal obstruction.~* All patients will complete the Visual Analog Scale (VAS) on nasal obstruction before and after decongestion at their preoperative visit. Patients that fail to report a score less than 5 after decongestion are likely to have bony rather than soft tissue hypertrophy. In these patients MAIT is unlikely to be an adequate surgical option, and they would derive a greater amount of benefit from SMR. Therefore these patients will be excluded from the study, and offered only SMR.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Microdebrider-Assisted Inferior Turbinoplasty (MAIT) (Type: EXPERIMENTAL): Turbinoplasty using microdebrider turbinate blade (2.9mm inferior turbinate blade, Medtronic, 5000 Hz)
- Submucous Resection (SMR) (Type: EXPERIMENTAL): Turbinoplasty using non-powered instruments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed non-small cell lung cancer, including squamous cell carcinomas, adenocarcinomas and non-neuroendocrine large cell carcinomas~* Patients with advanced stages of NSCLC who are candidates to first-line platinum-based doublet chemotherapy~* Measurable disease by RECIST 1.1~* Age ≥ 18 years.~* Performance status 0-2.~* Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion):~  * White blood cells (WBC) ≥ 3.0 \* 10\^9/l or neutrophils (ANC) ≥ 1.5 \* 10\^9/l~ * Platelet count ≥ 100 \* 10\^9/l~ * Hemoglobin ≥ 6 mmol/l~ * Serum bilirubin \< 2.0 \* upper level of normal (ULN)~ * Serum transaminase ≤ 2.5 \* ULN~ * Serum creatinine ≤ 1.5 ULN~* Written and orally informed consent.~Exclusion Criteria:~* Other malignant diseases within 5 years prior to inclusion in the study, except curatively treated basal cell or squamous cell carcinoma of the skin and other types of cancer with minimal risk of recurrence.~* Other experimental therapy or participation in another clinical trial within 28 days prior to treatment initiation.~* Patients who have received prior chemotherapy for NSCLC~* Patients with NSCLC who are candidates to neoadjuvant chemotherapy or curative chemoradiotherapy~* Underlying disease not adequately treated (diabetes, cardiac disease)~* Allergy to the active substance or any of the auxiliary agents~* Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at screening is mandatory.~* Fertile patients not willing to use effective methods of contraception during treatment and for 6 months after the end of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Performance status 0-1, Arm A (Type: EXPERIMENTAL): Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Tocotrienol 300 mg x 3 daily until progression.
- Performance status 0-1, Arm B (Type: EXPERIMENTAL): Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Placebo 1 capsule x 3 daily until progression.
- Performance status 2, Arm A (Type: EXPERIMENTAL): Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Tocotrienol 300 mg x 3 daily until progression
- Performance status 2, Arm B (Type: EXPERIMENTAL): Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Placebo 1 capsule x 3 daily until progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age at least 18 years.~* Presence of symptoms of an ischemic stroke with a baseline National Institutes of Health Stroke Scale (NIHSS) scale of one up to 20 or due to an ipsilateral atherosclerotic \>50% stenosis of the extracranial internal carotid artery (ICA) as shown by ultrasonography.~* Latency between the onset of stroke symptoms and intended administration of the study drugs is not more than 24 hours.~* Latency between the intended administration of the study drugs and intended carotid endarterectomy is at least three days.~Exclusion Criteria:~* Documented peptic ulcer disease within the preceding 30 days.~* Septicemia or severe localized infection.~* Severe illness (active cancer or significant liver or renal disease) or disability.~* Alcohol or illicit drug abuse.~* Pregnancy.~* Need for chronic anticoagulant therapy (e.g. atrial fibrillation, deep venous thrombosis).~* Need for long-term daily nonsteroidal antiinflammatory drugs.~* Contraindications for platelet therapy such as severe bleeding disorder within the past three months prior to randomization (coagulopathy, platelet disorder including history of heparin-induced thrombopenia, hemorrhage) or significant retinopathy with hemorrhages and exudates.~* Hypersensitivity to abciximab, murine monoclonal antibodies or aspirin.~* Any preexisting intracranial neurological disease such as tumor or multiple sclerosis.~* Intracranial or intraspinal operation or trauma or lumbar puncture within the last 2 months.~* Cardiac lesions likely to cause cardioembolism.~* Suspicion of or established non-atherosclerotic carotid artery disease such as dissection or vasculitis (Takayasu disease, giant cell arteritis, significant collagen vascular disease, systemic necrotizing vasculitis, granulomatous angiitis of the nervous system).~* Participation in another acute stroke trial investigating drugs other than abciximab.~* Treatment for the present stroke with tissue plasminogen activator, urokinase or ancrod.~* ICH, aneurysm, vascular malformation or arteriovenous fistula or sinovenous thrombosis of the brain.~* Brain infarct involving the whole territory of the middle cerebral artery (MCA).~* Stupor or coma.~* Uncontrolled hypertension (systolic pressure \>200 mmHg and/or diastolic pressure \>110 mmHg).~* No informed consent.~* Contraindication to undergo magnetic resonance (MR) imaging (eg pacemaker).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Establish Implant Accuracy With X-PSI Knee System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is 18 years of age or older.~* Patient can follow the X-PSI Knee System imaging protocol as part of standard of care procedures.~* Patient gets TKA treatment which follows the criteria of the appropriate Instruction for Use.~* Patient is willing and able to cooperate in the required postoperative standard of care.~* Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.~* Patient has participated in the study-related Informed Consent process and has signed the Ethics Committee approved Informed Consent~Exclusion Criteria:~* Patient is unwilling or unable to give consent or to comply with the follow-up program.~* Patient meets exclusion criteria of the appropriate Instruction for Use~* Patients who have any condition which would in the judgement of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, or is a known drug abuser, a known alcoholic or anyone who cannot understand what is required from them~* Patient is known to be pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Total knee arthroplasty (Type: EXPERIMENTAL): Patients undergoing total knee arthroplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have cytologically/histologically documented solid tumor malignancies~* Age \> 18 years old~* Patients must be candidates to receive WBR for unresectable brain metastases~* Patients must have ECOG performance status 0-2~* Patients must be able to give informed consent and able to follow guidelines given in the study~* Neurologic Function Status 0,1, or 2~* The patient has no major impairment of hematological function, as defined by the following laboratory parameters: WBC \>3.0x10\^9/L; ANC \> 1.5 x 10\^9/L; Hgb \>9.0g/dL; PLT \>100x10\^9/L. Red blood cell transfusions and repeat evaluations for study entry are allowed~* Patients must have adequate renal and normal hepatic function (creatinine \< 1.5 x upper limit of normal (ULN), bilirubin and SGOT (AST), SGPT (ALT) within 1.5 x the upper institutional normal limits) obtained within 4 weeks prior to registration.~* All patients of reproductive potential must use an effective method of contraception during the study and six months following termination of treatment. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to female patients who are older than 50 years and have not had a menstrual cycle in more than one year).~* Women of childbearing age must have a negative pregnancy test~* Patients must have 10 mm or greater brain lesion on MRI scan performed within 4 weeks of enrollment~Exclusion Criteria:~* Prior whole brain radiation~* More than 1 active malignancy which may potentially cause brain metastasis~* Patients on phenytoin, carbamazepine, phenobarbital, felbamate, meropenem, rifampin (Levetiracetam will be permitted)~* Patients with active or any history of seizure disorders~* Patients with uncontrolled nausea and vomiting~* Chemotherapy, radiotherapy, or hormonal therapy within 2 weeks prior to entering the study or have not recovered from prior treatment-related toxicities (grade 2 or less)~* Patients receiving any other investigational agents~* Evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry.~* Leptomeningeal disease or hydrocephalous on MRI scan performed within 4 weeks of enrollment~* Pregnant and breast feeding women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temazolomide, Valproic Acid and Radiation (Type: EXPERIMENTAL): Temazolomide, Valproic Acid and Whole Brain Radiation Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues